CP-870,893 (Pfizer/VLST), a strong agonist of CD40, is a fully human IgG2 with well-proved antitumor immunity in patients with solid tumors, including melanoma and pancreatic cancer (Beatty et al. 2013; Vonderheide et al. 2007, 2013b). Here, CD40 is linked to melanoma.